Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 12Active not recruiting 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Small Cell Lung Carcinoma 15Recurrence 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Unresectable Locally Advanced or Metastatic Solid Tumors 1Squamous Cell Carcinoma of Head and Neck 1SCLC, Extensive Stage 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Medulloblastoma 1Lung 1Leukemia 1Head and Neck Neoplasms 1Extrapulmonary Neuroendocrine Cancer 1Extensive Stage Lung Small Cell Cancer 1Extensive Small Cell Lung Cancer 1Ependymoma 1ES-SCLC 1Carcinoma, Squamous Cell 1Carcinoma, Small Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

surufatinib 1irinotecan sucrosofate 1envafolimab 1anlotinib 1Vincristine 1Temozolomide 1Proton Therapy 1Positron Emission Tomography Computed Tomography 1Neoadjuvant Therapy 1Methotrexate 1Ifosfamide 1Etoposide 1Epirubicin 1Drug Therapy 1Brachytherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Osteosarcoma × Etoposide × Clear all
NCT05590572 2022-10-21

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1/2 Not yet recruiting
148 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡